Inhibitors of HSP90 and MEK, when combined, have strong anti-tumor effects in KRAS-mutant lung cancer patient-derived xenograft mouse models and in NSCLC xenograft mouse models, showing a three- to fourfold reduction in tumor weight compared to that of vehicle-treated controls (Yang et al., 2019). Here, KRAS is linked to neoplasm.